Difference between revisions of "Nedaplatin (Aqupla)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "analogue" to "analog") |
||
| (5 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: A second-generation cisplatin | + | Class/mechanism: A second-generation cisplatin analog with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. <ref>[https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=468844 NCI Drug Dictionary entry for nedaplatin]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 6: | Line 6: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Cervical cancer]] | ||
*[[Nasopharyngeal carcinoma]] | *[[Nasopharyngeal carcinoma]] | ||
| − | *[[Non-small cell lung cancer]] | + | *[[Non-small cell lung cancer, squamous]] |
| + | *[[Non-small cell lung cancer, EGFR-mutated]] | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' 254-S | *'''Code name:''' 254-S | ||
*'''Generic name:''' nedaplat | *'''Generic name:''' nedaplat | ||
*'''Brand name:''' Aqupla, Jiebaishu | *'''Brand name:''' Aqupla, Jiebaishu | ||
| − | |||
==References== | ==References== | ||
<references /> | <references /> | ||
| Line 21: | Line 22: | ||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
| + | [[Category:Cervical cancer medications]] | ||
[[Category:Nasopharyngeal carcinoma medications]] | [[Category:Nasopharyngeal carcinoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Non-small cell lung cancer, squamous medications]] | ||
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] | ||
| + | [[Category:NMPA approved drugs]] | ||
Latest revision as of 13:50, 23 September 2023
General information
Class/mechanism: A second-generation cisplatin analog with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. [1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
- Cervical cancer
- Nasopharyngeal carcinoma
- Non-small cell lung cancer, squamous
- Non-small cell lung cancer, EGFR-mutated
Also known as
- Code name: 254-S
- Generic name: nedaplat
- Brand name: Aqupla, Jiebaishu